<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>THE "NEW" PROSTATE CANCER INFOLINK</title><style><!--
/* Font Definitions */
@font-face
        {font-family:Helvetica;
        panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
        {font-family:Helvetica;
        panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:Tahoma;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
        {font-family:Georgia;
        panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0cm;
        margin-bottom:.0001pt;
        font-size:12.0pt;
        font-family:"Times New Roman","serif";}
h1
        {mso-style-priority:9;
        mso-style-link:"Heading 1 Char";
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:24.0pt;
        font-family:"Times New Roman","serif";
        font-weight:bold;}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:blue;
        text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
        {mso-style-priority:99;
        color:purple;
        text-decoration:underline;}
p
        {mso-style-priority:99;
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:12.0pt;
        font-family:"Times New Roman","serif";}
span.Heading1Char
        {mso-style-name:"Heading 1 Char";
        mso-style-priority:9;
        mso-style-link:"Heading 1";
        font-family:"Cambria","serif";
        color:#365F91;
        font-weight:bold;}
span.EmailStyle19
        {mso-style-type:personal-reply;
        font-family:"Calibri","sans-serif";
        color:#1F497D;}
.MsoChpDefault
        {mso-style-type:export-only;
        font-size:10.0pt;}
@page WordSection1
        {size:612.0pt 792.0pt;
        margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
        {page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for a link to a study wrt Zytiga.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> noreply+feedproxy@google.com [mailto:noreply+feedproxy@google.com] <br><br><b>Subject:</b> The Prostate Cancer InfoLink<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><div style='margin-left:24.0pt;margin-right:24.0pt' id=emailbody><table class=MsoNormalTable border=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td width="99%" valign=top style='width:99.0%;padding:0cm 0cm 0cm 0cm'><h1 style='margin:0cm;margin-bottom:.0001pt'><a href="https://prostatecancerinfolink.net" title="(https://prostatecancerinfolink.net)"><span style='font-size:16.5pt;font-family:"Arial","sans-serif";color:#888888;font-weight:normal;text-decoration:none'>The Prostate Cancer InfoLink</span></a> <o:p></o:p></h1></td><td width="1%" style='width:1.0%;padding:0cm 0cm 0cm 0cm'></td></tr></table><div class=MsoNormal align=center style='text-align:center;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'><hr size=2 width="100%" align=center></span></div><table class=MsoNormalTable border=0 cellpadding=0 id=itemcontentlist><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=1></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/3BrIT8j0Ldw/?utm_source=feedburner&utm_medium=email"><b><span style='font-size:13.5pt;font-family:"Arial","sans-serif";color:#000099;text-decoration:none'>Low-dose abiraterone with food proves its worth in small Phase II trial</span></b></a> <o:p></o:p></p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:#555555'>Posted: 06 Apr 2018 09:04 AM PDT<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'>We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. The […]<o:p></o:p></span></p></div></td></tr></table><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black;display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=1 cellpadding=0 width="100%" style='width:100.0%;border:none;border-top:solid #999999 1.0pt' id=footer><tr><td style='border:none;padding:3.0pt .75pt .75pt .75pt'></td><td valign=top style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal align=right style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm;text-align:right'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Email delivery powered by Google<o:p></o:p></span></p></td></tr><tr><td colspan=2 style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States<o:p></o:p></span></p></td></tr></table><p class=MsoNormal><o:p> </o:p></p></div></div></body></html>